Band 2
Provided by Xudong Tao
Mr. Tao has over 25 years of experience practicing law in the PRC, focusing on debt and equity financing by PRC companies in both domestic and overseas markets, including advising issuers, underwriters and investors in connection with IPO and listing on the capital markets of the PRC, Hong Kong and USA, and post-listing restructuring, mergers and acquisitions, take-private and re-listing transactions.
Mr. Tao’s most recent representative deals include: (a) acting as PRC counsel to Grifols S.A. in its strategic investment in SSE-listed SRAAS in 2018 and divest in 2024; (b) acting as the issuer or underwriter’s PRC counsel to the HKIPO and listing on HKEX by QuantumParm, Qyun Therapeutics (2024), JF Wealth, DPC Dash (2023), AIM Vaccine (2022) and Microport Medbot (2021); (c) acting as the issuer’s counsel to IPO in the PRC and listing on PRC STAR Market by Biokin Pharma (2023), Hinova Pharma, Transwarp (2022), BeiGene (2021), Zelgen Biopharma and HitGen (2020), etc.
Mr. Tao has been selected as “Leading Lawyer” in capital market and mergers and acquisitions areas by Asialaw and IFLR since 2012. He is also ranked as a “Recommended Lawyer” by Chambers in corporate and commercial area (Band I) and a “Stand-out Lawyers” by Thomson Reuters in 2021.
Member of the All China Bar Association
Provided by Chambers
Tao Xudong of JunHe has a well-established practice in the capital markets space in Shanghai and is adroit at handling high-value financing transactions, corporate restructuring projects and M&A deals. He is also active as a commercial arbitrator.
15 items provided by JunHe LLP
JunHe Recognized in the 2024 Boutique Legal Service Brands Guide and 19 Partners Named Brand Stars
On April 19, 2025, Lexpress’ Legal Innovation Development Forum & 2025 Spring Release of the Lexpress Guide were held in Beijing. JunHe was recognized as one of the Most Influential Law Firm Brands in the areas of construction, capital markets, biomedicine and healthcare.
JunHe Advises on Zhaojin Mining’s HKD 1.98 billion H-Share Placement
On March 31, 2025, Zhaojin Mining Industry Co., Ltd. (Zhaojin Mining, stock code: 1818.HK) announced the successful placement of 140 million H shares.
JunHe Assisted Hinova Pharma in its Successful STAR Market IPO
On April 12, 2022, Hinova Pharmaceuticals Inc. ( “Hinova Pharma” or the “Company”, stock code: 688302) was successfully listed on the Shanghai Stock Exchange STAR Market ( the “Project”). JunHe acted as the counsel to the issuer.
JunHe Assists SDIC Juli in Strategic Investment in Moon Biotech
Recently, SDIC Juli Investment Management Co., Ltd. ("SDIC Juli") completed a strategic investment of nearly RMB 300 million in Moon (Guangzhou) Biotech Co., Ltd. ("Moon Biotech").
JunHe advises Grifols in the sale of a 20% equity stake in SRAAS and its strategic alliance with Hai
On June 18, 2024, Grifols, S.A. ("Grifols"), a global healthcare company and a leading producer of plasma-derived medicines, announced completion of the sale of a 20% equity stake in Shanghai RAAS (“SRAAS”) to Haier Group Corporation (“Haier Group”) for RMB 12.5 billion (approximately USD 1.8 billio
JunHe Assists QuantumPharm to List on the Hong Kong Stock Exchange, Becoming the First Stock listed
On 13 June 2024, QuantumPharm Inc. ("QuantumPharm" or the "Company"; Stock Code: 2228.HK) was listed on the Main Board of the Hong Kong Stock Exchange. QuantumPharm is the first stock to be listed under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hon
JunHe Advises Ascentage Pharma on its NASDAQ Listing
On January 24, 2025, Ascentage Pharma Group International ("Ascentage Pharma", the "Company" or the "Issuer") (NASDAQ: AAPG, HKEX: 06855) issued 7,325,000 American depositary shares and was listed on the NASDAQ, raising funds exceeding USD 126 million.
JunHe Advises XtalPi Holdings on its New Share Placement
JunHe acted as the PRC legal counsel to the placement agent in a new share placement by XtalPi Holdings Limited (stock code: 2228.HK). A total of 264 million new shares were issued, generating approximately HKD 1.13 billion in net proceeds, making it one of the largest new share placements in HK.
Four JunHe Cases Make the List of Belt and Road Legal Service Typical Cases
On September 8, the 2024 Results Release Session of the Typical Cases of the Belt and Road Legal Service was held in Xiamen, Fujian Province. It was hosted by the Belt and Road Legal Research Center of the China University of Political Science and Law and supported by Legal Daily and legaldaily.com.
JunHe Advises Planet Image on its NASDAQ Listing
On January 25, 2024, Planet Image International Limited (“Planet Image” or the “Company”) was successfully listed on the NASDAQ, with the ticker symbol “YIBO”.
JunHe Advises Qyuns on its Listing on the Stock Exchange of Hong Kong
On Mar. 20, 2024, Qyuns Therapeutics (02509.HK) issued 12,046,400 H shares globally and listed on the HK Stock Exchange's Main Board. It's the first in its biopharmaceutical niche and under Chapter 18A to list in HK after the New Rules for Overseas Listing.
JunHe Advises Zhaojin Mining on its HK$1.7 Billion H Share Placement
On April 22, 2024, Zhaojin Mining (1818.HK) completed a placement of 132m new H shares at HK$13.20, raising about HK$1.74bn , marking the largest such placement in the non-ferrous metals industry in Hong Kong since 2022.
JunHe helps QuantumPharm become the first to list on HKEX under new Chapter 18C rules
On 13 June 2024, QuantumPharm Inc. was listed on the Main Board of the Hong Kong Stock Exchange. QuantumPharm is the first stock to be listed under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hong Kong Stock Exchange.
JunHe guides Grifols in SRAAS equity sale and Haier alliance
On June 18, 2024, Grifols sold a 20% stake in SRAAS to Haier Group for RMB 12.5 billion, retaining a 6.58% stake and forming a strategic alliance with Haier and SRAAS. (Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group).
JunHe Assists SDIC Juli in Strategic Investment in Moon Biotech
Recently, SDIC Juli Investment Management Co., Ltd. ("SDIC Juli") completed a strategic investment of nearly RMB 300 million in Moon (Guangzhou) Biotech Co., Ltd. ("Moon Biotech").
JunHe Recognized in the 2024 Boutique Legal Service Brands Guide and 19 Partners Named Brand Stars
On April 19, 2025, Lexpress’ Legal Innovation Development Forum & 2025 Spring Release of the Lexpress Guide were held in Beijing. JunHe was recognized as one of the Most Influential Law Firm Brands in the areas of construction, capital markets, biomedicine and healthcare.
JunHe Advises on Zhaojin Mining’s HKD 1.98 billion H-Share Placement
On March 31, 2025, Zhaojin Mining Industry Co., Ltd. (Zhaojin Mining, stock code: 1818.HK) announced the successful placement of 140 million H shares.
JunHe Assisted Hinova Pharma in its Successful STAR Market IPO
On April 12, 2022, Hinova Pharmaceuticals Inc. ( “Hinova Pharma” or the “Company”, stock code: 688302) was successfully listed on the Shanghai Stock Exchange STAR Market ( the “Project”). JunHe acted as the counsel to the issuer.
JunHe Assists SDIC Juli in Strategic Investment in Moon Biotech
Recently, SDIC Juli Investment Management Co., Ltd. ("SDIC Juli") completed a strategic investment of nearly RMB 300 million in Moon (Guangzhou) Biotech Co., Ltd. ("Moon Biotech").
JunHe advises Grifols in the sale of a 20% equity stake in SRAAS and its strategic alliance with Hai
On June 18, 2024, Grifols, S.A. ("Grifols"), a global healthcare company and a leading producer of plasma-derived medicines, announced completion of the sale of a 20% equity stake in Shanghai RAAS (“SRAAS”) to Haier Group Corporation (“Haier Group”) for RMB 12.5 billion (approximately USD 1.8 billio
JunHe Assists QuantumPharm to List on the Hong Kong Stock Exchange, Becoming the First Stock listed
On 13 June 2024, QuantumPharm Inc. ("QuantumPharm" or the "Company"; Stock Code: 2228.HK) was listed on the Main Board of the Hong Kong Stock Exchange. QuantumPharm is the first stock to be listed under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hon
JunHe Advises Ascentage Pharma on its NASDAQ Listing
On January 24, 2025, Ascentage Pharma Group International ("Ascentage Pharma", the "Company" or the "Issuer") (NASDAQ: AAPG, HKEX: 06855) issued 7,325,000 American depositary shares and was listed on the NASDAQ, raising funds exceeding USD 126 million.
JunHe Advises XtalPi Holdings on its New Share Placement
JunHe acted as the PRC legal counsel to the placement agent in a new share placement by XtalPi Holdings Limited (stock code: 2228.HK). A total of 264 million new shares were issued, generating approximately HKD 1.13 billion in net proceeds, making it one of the largest new share placements in HK.
Four JunHe Cases Make the List of Belt and Road Legal Service Typical Cases
On September 8, the 2024 Results Release Session of the Typical Cases of the Belt and Road Legal Service was held in Xiamen, Fujian Province. It was hosted by the Belt and Road Legal Research Center of the China University of Political Science and Law and supported by Legal Daily and legaldaily.com.
JunHe Advises Planet Image on its NASDAQ Listing
On January 25, 2024, Planet Image International Limited (“Planet Image” or the “Company”) was successfully listed on the NASDAQ, with the ticker symbol “YIBO”.
JunHe Advises Qyuns on its Listing on the Stock Exchange of Hong Kong
On Mar. 20, 2024, Qyuns Therapeutics (02509.HK) issued 12,046,400 H shares globally and listed on the HK Stock Exchange's Main Board. It's the first in its biopharmaceutical niche and under Chapter 18A to list in HK after the New Rules for Overseas Listing.
JunHe Advises Zhaojin Mining on its HK$1.7 Billion H Share Placement
On April 22, 2024, Zhaojin Mining (1818.HK) completed a placement of 132m new H shares at HK$13.20, raising about HK$1.74bn , marking the largest such placement in the non-ferrous metals industry in Hong Kong since 2022.
JunHe helps QuantumPharm become the first to list on HKEX under new Chapter 18C rules
On 13 June 2024, QuantumPharm Inc. was listed on the Main Board of the Hong Kong Stock Exchange. QuantumPharm is the first stock to be listed under Chapter 18C of the New Rules Governing the Listing of Specialized Technology Companies on the Hong Kong Stock Exchange.
JunHe guides Grifols in SRAAS equity sale and Haier alliance
On June 18, 2024, Grifols sold a 20% stake in SRAAS to Haier Group for RMB 12.5 billion, retaining a 6.58% stake and forming a strategic alliance with Haier and SRAAS. (Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group).
JunHe Assists SDIC Juli in Strategic Investment in Moon Biotech
Recently, SDIC Juli Investment Management Co., Ltd. ("SDIC Juli") completed a strategic investment of nearly RMB 300 million in Moon (Guangzhou) Biotech Co., Ltd. ("Moon Biotech").